Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-5241EnglishN2023December21Pharmaceutical SciencesMetal–Curcumin Complexes in Modern Pharmacotherapeutics: A Comprehensive Review     English0107Maheshwar RathoreEnglish Arin BhattacharyaEnglishDr. Arin Bhattacharya, Professor, Department of Pharmacology, J. K. College of Pharmacy, Bilaspur 495001, Chhattisgarh, India.https://doi.org/10.31782/IJMPS.2023.131201The major ingredient in turmeric, curcumin, has drawn a lot of interest as a plant-based substance having pharmacological benefits that are pleiotropic. It has immunomodulatory, neuroprotective, antibacterial, anti-inflammatory, antioxidant, hypoglycemic, and anti-inflammatory properties. Curcumin has certain health-promoting properties, but they are limited by its hydrophobicity, insolubility in water, low bioavailability, quick metabolism, and systemic elimination. Complexes of metals with curcumin have been created as a result of this unique step. The -diketone moiety of curcumin often interacts with metals to form metal-curcumin complexes. It is generally known that the metal ions of boron, cobalt, copper, gallium, gadolinium, gold, lanthanum, manganese, nickel, iron, palladium, platinum, ruthenium, silver, vanadium, and zinc are all highly chelated by curcumin. Metal-curcumin complexes’ pharmacological, chemo-preventive, and therapeutic properties are described in this paper. Metal-curcumin complexes boost the antioxidant, anti-inflammatory, antibacterial, and antiviral properties of curcumin by increasing its solubility, cellular absorption, and bioavailability. Additionally, metal-curcumin complexes have shown effectiveness against a number of chronic illnesses, such as cancer, rheumatoid arthritis, osteoporosis, and neurological conditions including Alzheimer’s disease. The regulation of inflammatory mediators, transcription factors, protein kinases, antiapoptotic proteins, lipid peroxidation, and antioxidant enzymes was linked to these biological activities of metal-curcumin complexes. Metal-curcumin complexes have also proven beneficial in radio-imaging and biological imaging. Future applications of metal-curcumin complexes might signal a fresh strategy for the management of chronic illnesses. EnglishCurcumin, Metal, Complex, Synthesis, Therapeutics, Diagnosticshttp://ijcrr.com/abstract.php?article_id=241http://ijcrr.com/article_html.php?did=2411. Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the golden spice: From kitchen toclinic. Mol. Nutr. Food Res. 2013; 57:1510–1528. 2. Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK., Prasad S, et al. Curcumin, the golden nutraceutical: Multitargeting for multiple chronic diseases. Br. J. Pharmacol. 2017; 174:1325–1348. 3. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: From bedside to bench and back. Biotechnol. Adv. 2014; 32:1053–1064. 4. Aggarwal BB, Deb L, Prasad S. Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses. Molecules 2015; 20:185–205. 5. Priyadarsini KI. The chemistry of curcumin: From extraction to therapeutic agent. Molecules 2014; 19:20091–20112. 6. Salem M, Rohani S, Gillies ER. Curcumin, a promising anti-cancer therapeutic: A review of its chemical properties, bioactivity and approaches to cancer cell delivery. RSC Adv. 2014; 4: 10815–10829. 7. Mary CPV, Vijayakumar S, Shankar R. Metal chelating ability and antioxidant properties of curcumin–metal complexes— ADFT approach. J. Mol. Gr. Modell. 2018; 79: 1–14. 8. Gupta H, Gupta M, Bhargava S. Potential use of turmeric in COVID-19. Clin. Exp. Dermatol. 2020; 45:902–903. 9. Vellampatti S, Chandrasekaran G, Mitta SB, Lakshmanan VK, Park SH. Metallo-curcumin-conjugated DNA complexesinduces preferential prostate cancer cells cytotoxicity and pause growth of bacterial cells. Sci. Rep. 2018; 8:14929–14939. 10. Khalil MI, Al-Zahem AM, Al-Qunaibit MH. Synthesis, characterization, mössbauer parameters, and antitumor activity ofFe(III) curcumin complex. Bioinorg. Chem. Appl. 2013; 2013:982423. 11. Barik A, Mishra B, Kunwar A, Kadam RM, Shen L, Dutta S, et al. Comparative study of Copper(II)-curcumin complexes as superoxide dismutase mimics and free radical scavengers. Eur. J. Med. Chem. 2007; 42:431–439. Leung MHM, Harada T, Kee TW. Delivery of curcumin and medicinal effects of the Copper (II)-curcumin complexes. Curr. Pharm. Des. 2013; 19:889-897. 13. Vajragupta O, Boonchoong P, Watanabe H, Tohda M, Kummasud N, Sumanont Y. Manganese complexes of curcumin andits derivatives: Evaluation for the radical scavenging ability and neuroprotective activity. Free Rad. Biol. Med. 2003; 35:1632– 1644. 14. Hieu TQ, Thao DTT. Enhancing the solubility of curcumin metal complexes and investigating some of their biological activities. J. Chem. 2019; 2019:1–9. 15. Subhan MA, Alam K, Rahaman MS, Rahman MA, Awal R. Synthesis and characterization of metal complexes containingcurcumin (C21H20O6) and study of their antimicrobial activities and DNA-binding properties. J. Sci. Res. 2013; 6:97–109. 16. Shakeri A, Panahi Y, Johnston TP, Sahebkar A. Biological properties of metal complexes of curcumin. BioFactors 2019; 45:304–317. 17. Mei X, Xu D, Xu S, Zheng Y, Xu S. Gastroprotective and antidepressant effects of a New Zinc (II)-curcumin complex in rodent models of gastric ulcer and depression induced by stresses. Pharmacol. Biochem. Behav. 2011; 99:66–74. 18. Ahmed SA, Hasan MN, Bagchi D, Altass HM, Morad M, Jassas RS, et al. Combating essential metal toxicity: Key information from optical spectroscopy. ACS Omega 2020; 5:15666–15672. 19. Singh DK, Jagannathan R, Khandelwal P, Abraham PM, Poddar P. In Situ synthesis and surface functionalization of gold nanoparticles with curcumin and their antioxidant properties: An experimental and density functional theory investigation. Nanoscale 2013; 5: 1882–1893. 20. Lyu Y, Yu M, Liu Q, Zhang Q, Liu Z, Tian Y, et al. Synthesis of silver nanoparticles using oxidized amylase and combination with curcumin for enhanced antibacterial activity. Carbohydr. Polym. 2020; 230:115573. 21. Yan FS, Sun JL, Xie WH, Shen L, Ji HF. Neuroprotective effects and mechanisms of curcumin–Cu(II) and–Zn(II) complexes systems and their pharmacological implications. Nutrients 2018; 10:28. 22. Singh A, Dutta PK. Green synthesis, characterization and biological evaluation of chitin glucan based zinc oxide nano particles and its curcumin conjugation. Int. J. Biol. Macromol. 2020;156: 514–521. 23. Antonyan A, De A, Vitali LA, Pettinari R, Marchetti F, Gigliobianco MR, et al. Evaluation of (Arene) Ru(II) complexes of curcumin as inhibitors of dipeptidyl peptidase IV. Biochimie 2014; 99:146–152. 24. Jahangoshaei P, Hassani L, Mohammadi F, Hamidi A, Mohammadi K. Investigating the effect of gallium curcumin and gallium diacetyl curcumin complexes on the structure, function and oxidative stability of the peroxidase enzyme and their anticancer and antibacterial activities. J. Biol. Inorg. Chem. 2015; 20:1135–1146. 25. Mei X, Xu D, Xu S, Zheng, Y., Xu, S. Novel role of Zn(II)- curcumin in enhancing cell proliferation and adjusting proinflammatory cytokine-mediated oxidative damage of ethanol-induced acute gastric ulcers. Chem. Biol. Interact. 2012;197: 31–39. 26. Mei X, Luo X, Xu S, Xu D, Zheng Y, Xu S, et al. Gastroprotective effects of a new Zinc(II)-curcumin complex against pylorusligature- induced gastric ulcer in rats. Chem. Biol. Interact. 2009; 181:316–321. 27. Kunwar A, Narang H, Indira Priyadarsini K, Krishna M, Pandey R, Sainis KB. Delayed activation of PKCδ and NFκB and higher radioprotection in splenic lymphocytes by Copper (II)-Curcumin (1:1) complex as compared to curcumin. J. Cell. Biochem. 2007; 102: 1214–1224. 28. Seeta Rama Raju G, Pavitra E, Purnachandra Nagaraju G, Ramesh K, El-Rayes BF, Yu JS. Imaging and curcumin delivery in pancreatic cancer cell lines using PEGylated α-Gd2 (MoO4)3 mesoporous particles. Dalton Trans. 2014; 43:3330–3338. 29. Kareem A, Arshad M, Nami SAA, Nishat N. Herbo-mineral based schiff base ligand and its metal complexes: Synthesis, characterization, catalytic potential and biological applications. J. Photochem. Photobiol. B Biol. 2016;160:163–171. 30. Papadimitriou A, Ketikidis I, Stathopoulou MEK, Banti CN, Papachristodoulou C, Zoumpoulakis L, et al. Innovative material containing the natural product curcumin, with enhanced antimicrobial properties for active packaging. Mater. Sci. Eng. C 2018; 84:118–122. 31. Srivastava P, Shukla M, Kaul G, Chopra S, Patra AK. Rationally designed curcumin based Ruthenium(II) antimicrobials effective against drug-resistant: Staphylococcus aureus. Dalton Trans. 2019; 48 :11822–11828. 32. Das S, Mukhopadhyay K, Saha T, Kumar P, Sepay N, Ganguly D, et al. Multitargeting antibacterial activity of a synthesized Mn2+ complex of curcumin on gram-positive and gram-negative bacterial strains. ACS Omega 2020; 5:16342–16357. 33. Chauhan G, Rath G, Goyal A.K. In-vitro anti-viral screening and cytotoxicity evaluation of copper-curcumin complex. Artif. Cells Nanomed. Biotechnol. 2013; 41:276–281. 34. Gholami M, Zeighami H, Bikas R, Heidari A, Rafiee F, Haghi F. Inhibitory activity of metal-curcumin complexes on quorum sensing related virulence factors of Pseudomonas AeruginosaPAO1. AMB Express 2020;10:111–120. 35. Katsipis G, Tsalouxidou V, Halevas E, Geromichalou E, Geromichalos G, Pantazaki, A.A. In vitro and in silico evaluation of the inhibitory effect of a curcumin-based Oxovanadium (IV) complex on alkaline phosphatase activity and bacterial biofilm formation. Appl. Microbiol. Biotechnol. 2021;105:147–168. 36. Sui Z, Salto R, Li J, Craik C, Ortiz de Montellano PR. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg. Med. Chem. 1993;1:415–422. 37. Refat MS. Synthesis and characterization of ligational behavior of curcumin drug towards some transition metal ions: Chelation effect on their thermal stability and biologicalactivity. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2013;105:326–337. 38. Barclay LRC, Vinqvist MR, Mukai K, Goto H, Hashimoto Y, Tokunaga A, et al. On the antioxidant mechanism of curcumin: Classical methods are needed to determine antioxidant mechanism and activity. Org. Lett. 2000;2:2841–2843. 39. Gupta N, Verma K, Nalla S, Kulshreshtha A, Lall R, Prasad S. Free radicals as a double-edged sword: The cancer preventive and therapeutic roles of curcumin. Molecules 2020;25:5390. 40. Jakubczyk K, Druzga A, Katarzyna J, Skonieczna-zydeckaK. Antioxidant potential of curcumin—A meta-analysis of randomized clinical trials. Antioxidants. 2020;9:1092. 41. Priya RS, Balachandran S, Daisy J, Mohanan PV. Reactive centers of curcumin and the possible role of metal complexes of curcumin as antioxidants. Univ. J. Phys. Appl. 2015, 9:6–16. 42. Thakam A, Saewan N. Antioxidant activities of curcumin–metal complexes. Thail. J. Agric. Sci. 2011; 44:188–193. 43. Eybl V, Kotyzová D, Lešetický L, Bludovská M, Koutenský J.  The influence of curcumin and manganese complex of curcumin on cadmium-induced oxidative damage and trace elements status in tissues of mice. J. Appl. Toxicol. 2006; 26:207–212.  44. Meza-Morales W, Mirian Estévez-Carmona M, Alvarez-Ricardo Y, Obregón-Mendoza MA, Cassani J, Ramírez-Apan MT, et al. Full structural characterization of homoleptic complexes of diacetyl curcumin with Mg, Zn, Cu, and Mn: Cisplatinlevel cytotoxicity in vitro with minimal acute toxicity in vivo. Molecules 2019; 24: 1598. 45. Prasad S, Tyagi AK. Curcumin and its analogues: A potential natural compound against HIV infection and AIDS. Food Funct. 2015; 6:3412–3419. 46. Sandhya P, Renu K. Stabilisation of curcumin with ferrous ion and evaluation of its pharmacological property. Int. J. Pharmacogn. Phytochem. Res. 2015; 7:943–947. 47. Kali A, Bhuvaneshwar, D., Charles, P.M.V., Seetha, K. Antibacterial synergy of curcumin with antibiotics against biofilm producing clinical bacterial isolates. J. Basic Clin. Pharm. 2016; 7:93–96. 48. Agel MR, Baghdan E, Pinnapireddy SR, Lehmann J, Schäfer J, Bakowsky U. Curcumin loaded nanoparticles as efficient photoactive formulations against gram-positive and gramnegative bacteria. Coll. Surf. B Biointerfaces 2019;178:460– 468. 49. Jeyaraman P, Samuel M, Johnson A, Raman N. Synthesis, characterization, ADMET, in vitro and in vivo studies of mixed ligand metal complexes from a curcumin schiff base and lawsone. Nucleosides Nucleotides Nucl. Acids 2020;40:242–263. 50. Song YM, Xu JP, Ding L, Hou Q, Liu JW, Zhu ZL. Syntheses, characterization and biological activities of rare earth metal complexes with curcumin and 1,10-phenanthroline-5,6-dione. J. Inorg. Biochem. 2009; 103:396–400. 51. Maher KA, Mohammed SR. Metal complexes of Schiff base derived from salicylaldehyde-A review. Int J Curr Res Rev. 2015;7(2):6-16.

Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-5241EnglishN2023December21Pharmaceutical SciencesRevisiting New Classes of Chalcones from Antidiabetic Perspectives     English0713Suman UraihaEnglish Jyoti MaitryEnglish Lata Patel ChoudharyEnglish Yogesh PounikarEnglishMs. Suman Uraiha, Post Graduate Student, Department of Pharmaceutical Chemistry, J. K. College of Pharmacy, Bilaspur 495550, Chhattisgarh, Indiahttps://doi.org/10.31782/IJMPS.2023.131202Elevated blood sugar levels and a plethora of other, more diverse diseases, including changes to protein, carbohydrate, and lipid metabolism, are the only hallmarks of diabetes mellitus. Recent research has shown that mice lacking PTP1B had better glucose tolerance, less diet-induced obesity, and insulin sensitivity in general. In the therapy of serious diabetic problems, natural chalcones have recently been discovered, which have superior selectivity and do not affect pharmacokinetics. This is in response to the present demand for improved PTP-1B inhibitors. No appropriate formulation has been developed for the inhibitors based on natural products chalcones as they have not been tested clinically for toxicological characteristics. The review article has extensively covered various unknown natural chalcone compounds, such as kuwanon J, kuwanon R, kuwanon V, isoliquiritigenin, xanthoangelol, xanthoangelol D, xanthoangelol E, xanthoangelolF, xanthoangelol K, 4-hydroxyderricin, 5,4’-dihydroxy-6,7-furanbavachalcone, licochalcone A, licochalcone B, licochalcone C, licochalcone D, licochalcone E, echinatin, laxichalcone, broussochalcone, macdentichalcone, (2E)1, 1-(5,7-dihydroxy-2,2-dimethyl-2H-benzopyran-8-yl)}3-phenyl-2-propen-1-one, often known as 2E(abyssinone-VI-4-O-methyl ether, 1-(5,7-dihydroxy-2,2,6-trimethyl-2H-benzopyran-8-yl)-3-(4-methoxyphenyl)-2-propen-1-one) show great promise as a diabetic medication because it can inhibit insulin degradation by targeting the therapeutic target protein tyrosine phosphatase 1B (PTP-1B). These chalcone-based PTP-1B inhibitors derived from natural products are not currently used in clinical trials and have not attracted much interest from contemporary medicine due to a lack of clinical investigation into their toxicological profiles necessary to create an appropriate formulation. These chalcone-based PTP-1B inhibitors may soon unlock new opportunities in diabetotherapeutics. EnglishChalcone, Molecular targets, Inhibitors, Antidiabetic, Mechanisms, PTP1Bhttp://ijcrr.com/abstract.php?article_id=242http://ijcrr.com/article_html.php?did=2421. Shivhare RS, Mahapatra DK. Medicinal Chemistry-II. Nagpur: ABD Publications Private Limited, 2019. 2. Godbole MD, Mahapatra DK, Khode PD. Fabrication and Characterization of Edible Jelly Formulation of Stevioside: A Nutraceutical or OTC Aid for the Diabetic Patients. InventiRapid: Nutraceuticals 2017;2017(2):1-9. 3. Kuhite NG, Padole CD, Amdare MD, Jogdand KR, Kathane LL, Mahapatra DK. Hippuric acid as the template material for the synthesis of a novel anti-diabetic 1,3,4-thiadiazole derivative. Indian J Pharm Biol Res 2017;5(3):42-45. 4. Gangane PS, Kadam MM, Mahapatra DK, Mahajan NM, Mahajan UN. Design and formulating gliclazide solid dispersion immediate release layer and metformin sustained release layer in bilayer tablet for the effective postprandial management of  diabetes mellitus. Int J Pharm Sci Res2018;9(9):3743-3756. 5. Puranik MP, Mahapatra DK. Medicinal Chemistry-III. Nagpur: ABD Publications Private Limited, 2019. 6. Mahapatra DK, Chhajed SS, Shivhare RS. Development of Murrayanine-Chalcone hybrids: An effort to combine two privilege scaffolds for enhancing hypoglycemic activity. Int J Pharm Chem Anal.2017;4(2):30-34. 7. Mahapatra DK, Dadure KM, Haldar AGM. Uracil substitution on a hippuric acid containing 1,3,4-thiadiazole scaffold: The exploration of the anti-hyperglycemic potential. Int J Med Sci ClinRes Rev. 2018;1(2):1-4. 8. Mahapatra DK, Bharti SK. Handbook of Research on Medicinal Chemistry: Innovations and Methodologies. New Jersey: Apple Academic Press, 2017. 9. Mahapatra DK, Bharti SK. Medicinal Chemistry with Pharmaceutical Product Development. New Jersey: Apple Academic Press, 2019. 10. Singh RK, Mishra AK, Kumar P, Mahapatra DK. Molecular Docking and In Vivo Screening of Some Bioactive Phenoxyacetanilide Derivatives as Potent Non-Steroidal Anti- Inflammatory Drugs. Int J Cur Res Rev. 2021;13(10):189-196. 11. Mahapatra DK, Asati V, Bharti SK. Recent therapeutic progress of chalcone scaffold bearing compounds as prospective antigout candidates. J Crit Rev. 2019;6(1):1-5. 12. Mahapatra DK, Bharti SK, Asati V. Anti-cancer chalcones: Structural and molecular target perspectives. Eur J Med Chem. 2015;98:69-114. 13. Mahapatra DK, Bharti, SK, Asati V. Chalcone scaffolds as anti-infective agents: Structural and molecular target perspectives. Eur J Med Chem. 2015;101:496-524. 14. Mahapatra DK, Asati V, Bharti SK. Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives. Eur J Med Chem. 2015;92:839- 865. 15. Mahapatra DK, Bharti SK. Therapeutic potential of chalcones as cardiovascular agents. Life Sci. 2016;148:154-172. 16. Chen RM, Hu LH, An TY, Li J, Shen Q. Natural PTP1B inhibitors from Broussonetia papyrifera. Bioorg Med Chem Lett. 2002;12:3387–3390. 17. Hoang DM, Ngoc TM, Da NT, Ha DT, Kim YH, Luon HV, et al. Protein tyrosine phosphatase 1B inhibitors isolated from Morusbombycis. Bioorg Med Chem Lett. 2009;19:6759–6761. 18. Zhang LB, Lei C, Gao LX, Li JY, Li J, Hou AJ. Isoprenylated flavonoids with PTP1B inhibition from Macaranga denticulata. Nat Prod Bioprospect. 2016;6:25–30.19. Na MK, Jang J, Njamen D, Mbafor JT, Fomum ZT, Kim BY, et al. Protein tyrosine phosphatase-1B inhibitory activity of isoprenylated flavonoids isolated from Erythrinamildbraedii. J Nat Prod. 2006;69:1572–1576. 20. Lei C, Zhang LB, Yang J, Gao LX, Li JY, Li J, et al. Macdentichalcone, a unique polycyclic dimeric chalcone from Macaranga denticulata. Tetrahedron Lett. 2016;57:5475–5478. 21. Yoon G, Lee W, Ki S, Cheon SH. Inhibitory effect of chalcones and their derivatives from Glycyrrhizainflata on protein tyrosine phosphatase 1B. Bioorg Med Chem Lett. 2009;19:5155–5157. 22. Park SJ, Choe YG, Kim JH, Chang KT, Lee HS, Lee DS. Isoliquiritigenin impairs insulin signaling and adipocyte differentiation through the inhibition of protein-tyrosine phosphatase 1B oxidation in 3T3-L1 preadipocytes. Food Chem Toxicol. 2016;93:5–12. 23. Li JL, Gao LX, Meng FW, Tang CL, Zhang RJ, Li JY, et al. PTP1B inhibitors from stems of Angelica keiskei (Ashitaba). Bioorg Med Chem Lett. 2015;25:2028–2032. 24. Ha MT, Seong SH, Nguyen TD, Cho WK, Ah KJ, Ma JY, et al. Chalcone derivatives from the root bark of Morus alba L. act as inhibitors of PTP1B and α-glucosidase. Phytochemistry. 2018;155:114-125. 25. Ren L, Li LZ, Huang J, Huang LZ, Li JH, Li YM, et al. New compounds from the seeds of Psoraleacorylifolia with their protein tyrosine phosphatase 1B inhibitory activity. J Asian Nat Prod Res. 2019:1-6. 26. Joshi SR, Standl E, Tong N, Shah P, Kalra S, Rathod R. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opin Pharmacother. 2015;16(13):1959-1981. 27. Teng H, Chen L. α-Glucosidase and α-amylase inhibitors from seed oil: A review of liposoluble substance to treat diabetes. Crit Rev Food Sci Nutr. 2017;57(16):3438-3448. 28. Ryu HW, Lee BW, Curtis-Long MJ, Jung S, Ryu YB, Lee WS, et al. Polyphenols from Broussonetiapapyrifera displaying potent α-glucosidase inhibition. J Agric Food Chem. 2009;58(1):202- 208. 29. Liu M, Yin H, Liu G, Dong J, Qian Z, Miao J. Xanthohumol, a prenylated chalcone from beer hops, acts as an α-glucosidase inhibitor in vitro. J Agric Food Chem. 2014;62(24):5548-5554. 30. Ha MT, Seong SH, Nguyen TD, Cho WK, Ah KJ, Ma JY, et al. Chalcone derivatives from the root bark of Morus alba L. act as inhibitors of PTP1B and α-glucosidase. Phytochem. 2018;155:114-125. 31. Kim JH, Ryu YB, Kang NS, Lee BW, Heo JS, Jeong IY, et al. Glycosidase inhibitory flavonoids from Sophoraflavescens. Biol Pharm Bull. 2006;29(2):302-305. 32. Rao RR, Tiwari AK, Reddy PP, Babu KS, Ali AZ, Madhusudana K, et al. New furanoflavonoids, intestinal α-glucosidase inhibitory and free-radical (DPPH) scavenging, activity from antihyperglycemic root extract of Derris indica (Lam.). Bioorg Med Chem. 2009;17(14):5170-5175. 33. Saltos MB, Puente BF, Faraone I, Milella L, De Tommasi N, Braca A. Inhibitors of α-amylase and α-glucosidase from Andromachiaigniaria Humb. &Bonpl. Phytochem Lett. 2015;14:45-50. 34. Sun H, Wang D, Song X, Zhang Y, Ding W, Peng X, et al. Natural prenylchalconaringenins and prenylnaringenins as antidiabetic agents: α-glucosidase and α-amylase inhibition and in vivo antihyperglycemic and antihyperlipidemic effects. J Agric Food Chem. 2017;65(8):1574-1581.